In short
Divarasib is an investigational drug being studied in several clinical trials for the treatment of advanced cancers, particularly non-small cell lung cancer (NSCLC) and colorectal cancer. These trials aim to evaluate the safety, efficacy, and pharmacokinetics of Divarasib, both as a single agent and in combination with other cancer therapies. The studies focus on patients with specific genetic mutations, such as KRAS G12C, and explore Divarasib's potential in various treatment settings.
At a glance
- Drug Name
- Divarasib (also known as GDC-6036)
- Cancer Types
- Non-small cell lung cancer (NSCLC), Metastatic colorectal cancer
- Target Population
- Patients with KRAS G12C mutations, Previously treated and untreated patients
- Administration
- Oral, once daily
- Study Types
- Phase 1, Phase 2, Phase 3 clinical trials
- Combination Therapies
- Cetuximab, Bevacizumab, FOLFOX, FOLFIRI, Pembrolizumab
- Primary Outcomes
- Safety, Efficacy (Objective Response Rate, Progression-Free Survival)
- Secondary Outcomes
- Duration of Response, Overall Survival, Quality of Life measures
What is Divarasib?
Divarasib is a new drug being studied for the treatment of certain types of cancer. It is also known by its alternative names RO7435846 and GDC-6036. Divarasib belongs to a class of drugs called targeted therapies, which are designed to attack specific features of cancer cells while minimizing damage to healthy cells.
How Divarasib Works
Divarasib is specifically designed to target a particular genetic mutation called KRAS G12C. This mutation is found in some types of cancer and plays a role in helping cancer cells grow and survive. By targeting this mutation, Divarasib aims to slow down or stop the growth of cancer cells.
Conditions Treated by Divarasib
Based on the clinical trials information, Divarasib is being studied for the treatment of:
- Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer. Divarasib is being tested in patients with advanced or metastatic NSCLC that has the KRAS G12C mutation.
- Metastatic Colorectal Cancer: Divarasib is also being studied in patients with colorectal cancer that has spread to other parts of the body (metastatic) and has specific biomarkers.
Clinical Trials Involving Divarasib
Several clinical trials are currently underway to evaluate the effectiveness and safety of Divarasib:
- Phase III trial for NSCLC: This large-scale study is comparing Divarasib to other KRAS G12C inhibitors (sotorasib or adagrasib) in patients with previously treated NSCLC.
- Drug interaction studies: Researchers are investigating how Divarasib interacts with other medications, such as itraconazole, digoxin, and rosuvastatin.
- Combination therapy studies: Divarasib is being tested in combination with other cancer treatments, including immunotherapy drugs like atezolizumab and chemotherapy drugs.
- Early-stage NSCLC study: A trial is evaluating Divarasib as a treatment before and after surgery for patients with early-stage NSCLC.
How Divarasib is Administered
Divarasib is typically taken orally (by mouth) once daily. The exact dosage and schedule may vary depending on the specific clinical trial and the patient's condition. In some studies, Divarasib is given in combination with other cancer treatments, such as chemotherapy or immunotherapy.
Potential Side Effects
As with all medications, Divarasib may cause side effects. The full range of potential side effects is still being studied in clinical trials. Common side effects observed in cancer treatments may include fatigue, nausea, diarrhea, and decreased appetite. Researchers are closely monitoring patients for any adverse events during the clinical trials.
Future Prospects for Divarasib
Divarasib is still in the experimental stage and is not yet approved for general use. The ongoing clinical trials will help determine its effectiveness and safety profile. If the results are positive, Divarasib could become an important new treatment option for patients with KRAS G12C-mutated cancers, particularly in lung and colorectal cancer.
It's important to note that while Divarasib shows promise, more research is needed to fully understand its benefits and risks. Patients interested in this treatment should discuss it with their healthcare providers and consider participating in clinical trials if eligible.